☆ 4.4 Article

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam

OPEN FORUM INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections

Victoria Gavaghan et al.

Summary: This case series examines the real-world usage of cefiderocol in treating carbapenem-resistant Gram-negative bacterial infections and its associated clinical outcomes. The study found that cefiderocol remains a viable option for treating these types of infections.

INFECTION (2023)

Add to Collection

News Item Infectious Diseases

Sulbactam-durlobactam for Acinetobacter pneumonia

Ammara Mushtaq et al.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Infectious Diseases

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye et al.

Summary: This study compares the efficacy and safety of sulbactam-durlobactam with colistin in the treatment of serious infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. The results show that sulbactam-durlobactam is non-inferior to colistin in terms of 28-day all-cause mortality and has a lower incidence of nephrotoxicity. Sulbactam-durlobactam could be an effective intervention for reducing mortality from carbapenem-resistant ABC infections.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

Pranita D. Tamma et al.

Summary: The Infectious Diseases Society of America (IDSA) has provided updated guidance on the treatment of antimicrobial-resistant infections, focusing on treating AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. The guidance is based on clinical experience, expert opinion, and a review of available literature, as published data on optimal treatment options are limited. This document emphasizes treatment approaches for infections in the United States, considering differences in resistance epidemiology and the availability of specific anti-infectives internationally.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Patrice Nordmann et al.

Summary: The objective of this study is to characterize isolates with reduced susceptibility to cefiderocol in patients receiving cefiderocol for nosocomial pneumonia or carbapenem-resistant infections. The study found that although the minimum inhibitory concentration of some isolates increased by more than 4-fold, they remained susceptible to cefiderocol. Mutations related to enzyme activity and protein were identified in the isolates, which may contribute to the decreased susceptibility to cefiderocol.

MICROBIAL DRUG RESISTANCE (2022)

Add to Collection

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Immunology

Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report

Dana J. Holger et al.

Summary: This study reports a case of a critically ill patient with extensively drug-resistant Acinetobacter baumannii necrotizing pneumonia complicated by empyema in Detroit, Michigan. A precision medicine approach was used to guide the rational combination antimicrobial therapy through whole-genome sequencing, susceptibility testing, and synergy analysis.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

James A. Karlowsky et al.

Summary: Sulbactam-durlobactam demonstrated potent antibacterial activity against geographically diverse clinical isolates of Acinetobacter baumannii-calcoaceticus complex (ABC), including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients

Kaitlin A. Pruskowski

Summary: Burn injuries can alter pharmacokinetic parameters, potentially leading to subtherapeutic doses of antibiotics and antifungal agents. Further research is needed to cover systemic antimicrobial agents used in the care of burn patients in order to make appropriate dosing adjustments.

SURGICAL INFECTIONS (2021)

Add to Collection

Article Microbiology

Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination

Noor Zaidan et al.

Summary: A successful case of treating XDR Acinetobacter baumannii pneumonia and septic shock with a novel antibiotic obtained via expanded access protocol was reported, suggesting that focused research and drug development efforts can mitigate the poor outcomes associated with these infections.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics

Milo Gatti et al.

Summary: In critically ill patients undergoing CRRT, dose optimization of antimicrobial agents is complicated by the impact of the extracorporeal circuit on pharmacokinetics and dynamic changes in renal function. The lack of pharmacokinetic data for novel antimicrobials during CRRT poses challenges for evidence-based dose recommendations. Further studies are needed to guide optimal dosing in this population.

CLINICAL PHARMACOKINETICS (2021)

Add to Collection

Review Infectious Diseases

Ever-Adapting RND Efflux Pumps in Gram-Negative Multidrug-Resistant Pathogens: A Race against Time

Martijn Zwama et al.

Summary: The rise in multidrug resistance poses a major threat to human health globally due to the over-expression of multidrug efflux pumps and amino acid substitutions within the pumps themselves causing increased drug efflux efficiency. Studies on clinically, environmentally and laboratory-evolved Gram-negative bacterial strains have shown mutations in the RND-type pumps leading to decreased drug sensitivity. Understanding the evolution and variations in efflux pumps is crucial for the development of novel antibiotics and efflux pump inhibitors.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Pharmacology & Pharmacy

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Sarah M. McLeod et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Community-acquired in name only: A cluster of carbapenem-resistant Acinetobacter baumannii in a burn intensive care unit and beyond

Erica S. Shenoy et al.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2020)

Add to Collection

Article Microbiology

Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3

Saquib Malik et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Unusual community-associated carbapenem-resistant Acinetobacter baumannii infection, Pennsylvania, USA

Mohamed H. Yassin et al.

IDCASES (2020)

Add to Collection

Article Microbiology

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Melissa D. Barnes et al.

MBIO (2019)

Add to Collection

Review Microbiology

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Microbiology

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii

Sarah M. McLeod et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Add to Collection

Article Microbiology

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Reville et al.

NATURE MICROBIOLOGY (2017)

Add to Collection

Article Microbiology

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Add to Collection

Article Microbiology

Analysis of Genes Encoding Penicillin-Binding Proteins in Clinical Isolates of Acinetobacter baumannii

Rodrigo Cayo et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)

Add to Collection

Article Immunology

Community-acquired carbapenem-resistant Acinetobacter baumannii urinary tract infection just after marriage in a renal transplant recipient

Y. Solak et al.

TRANSPLANT INFECTIOUS DISEASE (2011)

Add to Collection

Article Immunology

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

Robert A. Bonomo et al.

CLINICAL INFECTIOUS DISEASES (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.